U.S. Physical Therapy enters the back half of June with its most extreme options positioning of the past year — and the gap between where the stock trades and where analysts think it should be worth watching closely.
The options market is flashing the loudest signal in the data this week. The put/call ratio has surged to 9.95, the highest reading in the past twelve months and more than three-and-a-half standard deviations above its 20-day average of 3.95. That is not a subtle skew — it represents a sharp, sudden shift toward downside protection. The move came in two steps: the PCR jumped from roughly 3.88 to 7.21 on Monday, then extended again to 9.95 on Tuesday. For a mid-cap healthcare name that rarely generates options fireworks, this kind of demand for puts is worth flagging on its own terms.
Short interest adds a secondary layer to the cautious picture, though it tells a less urgent story than the options desk. Short interest in USPH has edged up about 5% over the past month to roughly 6.8% of free float — meaningful but not extreme. The week itself saw a modest trim of around 2.6%, pulling the count back from a recent peak near 1.07 million shares. Borrowing the stock remains cheap at 0.38%, down sharply from a brief spike above 2.3% in late May. Availability is ample at over 500% of short interest, meaning new shorts face no friction in establishing positions. The borrow market is relaxed; the pressure is coming from options, not the lending desk.
The Street broadly likes USPH but has been walking targets lower since the company's May earnings miss. Following that print, which sent the stock down roughly 19% in a single session, analysts at Citizens and Barrington Research each cut their price targets — to $98 and $90 respectively — while keeping positive ratings. Jefferies initiated with a Buy and a $102 target back in March. Today, Citizens reiterated its Market Outperform and held at $98. At a current price of $63.50, the mean analyst target of roughly $94 implies upside of close to 48%. That gap between market price and consensus is the dominant valuation story. The P/E of around 20.5x and EV/EBITDA near 14x are not stretched in isolation, but they look different when set against the margin compression bears are focused on. Factor scores underline the split: the forward EPS momentum rank is a strong 85th percentile, yet the EPS surprise rank is a weak 9th — the Street is optimistic about future earnings, but the company has been disappointing against near-term estimates.
A director, Peter Minan, made two small open-market purchases in early June — 780 shares combined at prices around $62-$63. The amounts are modest, but the timing is notable: he was buying into the post-earnings weakness, close to where the stock trades today. On the sell side, the COO and General Counsel cleared shares in March at prices well above $80, well before the May collapse — routine-looking in the context of where the stock was then.
The May earnings print is the critical piece of recent history. The stock fell nearly 20% on the day results hit and lost a further 11-16% over the following five sessions, making it the worst single-event reaction in the available data. The next results are due August 13. Between now and then, the question the options positioning raises is whether this week's put demand reflects fresh concern about the operational trajectory — margin recovery, labor costs, the hospital channel strategy — or simply a hedging response to the stock's continued drift below analyst targets. Either way, the August print looks set to be the moment that forces resolution.
See the live data behind this article on ORTEX.
Open USPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
